Linked Life Data

19581631

Source:http://linkedlifedata.com/resource/pubmed/id/19581631

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-8-4
pubmed:databankReference
pubmed:abstractText
More than 50% of patients who start efavirenz treatment develop limiting neuropsychiatric adverse events (NPAEs).
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1539-3704
pubmed:author
pubmed:issnType
Electronic
pubmed:day
4
pubmed:volume
151
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
149-56
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial.
pubmed:affiliation
Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, and Hospital Universitario de Valme, Seville, Spain.
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study